GlaxoSmith-Kline (GSK) Plc, UK has published its Corporate Responsibility report 2003 highlighting global investment in health sector and vaccination of HIV/AIDS in the developing countries.
The company would make investment in health and education activities worth £ 338 million, including humanitarian products donation of £ 105 million and £ 11 million to support the lymphatic filariasis elimination programme.
Over 11 million Combivir tablets to treat HIV/AIDS have been shipped to the developing countries at preferential prices.
According to a press release issued by the GSK Plc, UK here on Thursday the report reinforces GSK's commitment to responsible management of ethical, social and environmental concerns and in particular to play a leading role in supporting health care in the developing world.
The title of the report "Making a difference everyday" confirms progress in the diverse and extensive contribution the company is making to meet the needs of society across the globe.
Similarly, the company's annual report, "Improving performance every day," and annual review, "Improving health every day," have also been issued.
Commenting on the publication of the report, J.P. Garnier, CEO, GlaxoSmithKline said, "Corporate responsibility has particular resonance for the pharmaceutical sector. Our business is creating medicines and vaccines to treat and prevent disease - something that society needs and values.
He said this report deals with important issues relating to pharmaceutical business and measures to address the issues.-PR